Neupath Health Inc. Statistics
Neupath Health Inc. (NPTH) Stock Statistics & Valuation Metrics
Total Valuation
Neupath Health Inc. has a market cap or net worth of CAD 29.62M. The enterprise value is CAD 45.87M.
- Market Cap
- CAD 29.62M
- Enterprise Value
- CAD 45.87M
Share Statistics
Neupath Health Inc. has 54,844,310 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 54,844,310
- Owned by Insiders
- 5.60%
- Owned by Institutions
- ―
Financial Efficiency
Neupath Health Inc.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- ―
- Profits Per Employee
- -34.04K
- Employee Count
- 156
- Asset Turnover
- ―
- Inventory Turnover
- ―
Income Statement
In the last 12 months, Neupath Health Inc. had revenue of ― and earned -5.31M in profits. Earnings per share was ―.
- Revenue
- ―
- Gross Profit
- 9.96M
- Operating Income
- -661.00K
- Pretax Income
- ―
- Net Income
- -5.31M
- EBITDA
- -973.00K
- Earnings Per Share (EPS)
- ―
Stock Price Statistics
- Beta
- 1.16
- 52-Week Price Change
- 30.00%
- 50-Day Moving Average
- 0.55
- 200-Day Moving Average
- 0.56
- Relative Strength Index (RSI)
- 46.72
- Average Volume (3m)
- 70.71K
Important Dates
Neupath Health Inc. upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Balance Sheet
Neupath Health Inc. has ― in cash and marketable securities with CAD 9.57M in debt, giving a net cash position of ― billion.
- Cash & Marketable Securities
- ―
- Total Debt
- CAD 9.57M
- Net Cash
- ―
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- ―
Analyst Forecast
The average price target for Neupath Health Inc. is CAD 0.68, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- CAD 0.68
- Price Target Upside
- 30.77% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 6.31%
- EPS Growth Forecast
- ―

